Gilead Sciences reports exit of EVP, Corporate Affairs & GC

Rhea-AI Filing Summary

Gilead Sciences reported a leadership change affecting its legal and corporate affairs functions. The company announced that Deborah H. Telman will no longer serve as Executive Vice President, Corporate Affairs and General Counsel as of December 5, 2025. Her employment with the company will end later in December. This transition means Gilead will need to adjust leadership responsibilities in a key oversight and governance role, which can influence how the company manages legal risk, regulatory matters and external corporate communications.

Insights

Corporate governance analyst

Gilead announces the near-term departure of its EVP and General Counsel.

Gilead Sciences disclosed that Deborah H. Telman will cease serving as Executive Vice President, Corporate Affairs and General Counsel as of December 5, 2025, with her employment ending later that month. This role typically oversees legal strategy, governance processes and regulatory interactions.

The announcement does not describe any accompanying changes to strategy or financial guidance, so the immediate impact appears focused on leadership continuity in legal and corporate affairs. The effect on the business will largely depend on how quickly responsibilities are reassigned and whether a permanent successor is identified and integrated smoothly.

false 0000882095 0000882095 2025-11-15 2025-11-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): November 15, 2025

GILEAD SCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware	0-19731	94-3047598
(State or Other Jurisdiction of  Incorporation)	(Commission File No.)	(IRS Employer  Identification No.)

333 Lakeside Drive, Foster City, California

(Address of principal executive offices)

94404

(Zip Code)

650-574-3000

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value, $0.001 per share		GILD		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 19, 2025, Gilead Sciences, Inc., a Delaware corporation (the “Company”), announced that Deborah H. Telman will no longer serve as Executive Vice President, Corporate Affairs and General Counsel of the Company as of December 5, 2025. Ms. Telman’s employment with the Company will terminate later in the month.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GILEAD SCIENCES, INC.

(Registrant)

/s/ ANDREW D. DICKINSON

Andrew D. Dickinson

Chief Financial Officer

Date: November 19, 2025

FAQ

What leadership change did Gilead Sciences (GILD) announce on November 19, 2025?

Gilead Sciences announced that Deborah H. Telman will no longer serve as Executive Vice President, Corporate Affairs and General Counsel as of December 5, 2025, with her employment ending later in the month.

What position did Deborah H. Telman hold at Gilead Sciences (GILD)?

Deborah H. Telman served as Gilead Sciences’ Executive Vice President, Corporate Affairs and General Counsel, a senior leadership role overseeing legal and corporate affairs functions.

When will Deborah H. Telman step down from her role at Gilead Sciences?

She will stop serving as Executive Vice President, Corporate Affairs and General Counsel on December 5, 2025, and her employment with Gilead will terminate later in December 2025.

Does the Gilead Sciences 8-K mention any new appointment to replace Deborah H. Telman?

The disclosure only states that Deborah H. Telman will no longer serve in her role and that her employment will end later in December; it does not mention any replacement in this excerpt.

Why is Deborah H. Telman’s departure important for Gilead Sciences (GILD) investors?

As Executive Vice President, Corporate Affairs and General Counsel, Ms. Telman’s role covers legal oversight, governance and corporate affairs, which are important areas for compliance and risk management at Gilead.

What type of SEC filing did Gilead Sciences use to disclose Deborah H. Telman’s departure?

Gilead Sciences reported this leadership change in a Form 8-K, which is used to disclose significant current events to investors.